Ann: Primary Endpoint Successfully Achieved in MSB P3 GVHD Trial, page-31

I've just added my few cents worth into their thread =P

Today's results are relatively consistent with the 241 patient extended access program, which resulted in fast track designation and a stream-lined FDA phase 3 trial (to expedite its path to approval).

Extended access program (241 patients) showed:
Overall response rate of 65%
100 day survival at 82%
To me this means, 0.65 x 0.82 = 53.3% chance of survival

Today's phase 3 results show (50 patients to date, full trial 55 patients):
Overall response rate of 69%
100 day survival at 78% (or 22% mortality)
To me this means, 0.69 x 0.78 = 53.8% chance of survival

This compares to a 15% survival rate (85% mortality rate) for untreated patients.

In other words, when in the past a child who contracts aGVHD had 15% of survival... going forward, MSB's treatment will mean they will have over 53% chance of survival. I can understand why the FDA fast tracked this treatment, pat on the back to the team at MSB. Fantastic work!